Incepta pledges to continue innovation, diversification of Pharma products

The daylong annual sales conference-2024 of Incepta, a leading pharmaceutical company, was held at the International Convention City Bashundhara in the city on Saturday, said a press releaase.
Chairman and Managing Director of Incepta Abdul Muktadir and Vice Chairman Hasneen Muktadir attended the conference.
Abdul Muktadir said the various success stories and challenges of Incepta during the past years, and discussed the vision in future and motivated the participants to become successful both in the local and overseas market.
He emphasised on the successful worldwide export of its diversified range of products including vaccine and diaper.
Hasneen Muktadir said that from the beginning of its journey, Incepta is launching market demanding medicines every year at an affordable price while maintaining high quality to ensure the benefit and convenience of everyone. Incepta is the only pharmaceutical company in Bangladesh who launched two biosimilar biologics with its own API.
In 2022, Incepta produced and marketed the most awaited cervical cancer vaccine with an aim to make Bangladesh a cervical cancer free nation. In 2023, Incepta launched pneumococcal vaccine which is a life-saving product that was scarce in the market previously.
Incepta is committed to its vision to become a trusted healthcare company to ensure better health for everyone, everywhere.
Over the years for their contribution to industrialization, environment protection, employment generation, and economic development of the country, Incepta has been honored with numerous recognitions; such as "National Export Trophy (Silver)" for the fiscal year of 2020-2021, "President's Award for Industrial Development 2020", "Green Factory Award 2020", and "National Environment Medal 2022".